You are here

No Proof of Heart Risks from Parkinson’s drug

FDA finds no evidence of cardiovascular risks related to Novartis’ Stalevo

The FDA said Monday that there was no evidence of increased cardiovascular risks related to the use of carbidopa/levodopa/entacapone (Stalevo, Novartis) for Parkinson’s disease.

According to Reuters, recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels after the FDA examined data from a required clinical trial and one additional study.  The review found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease.

A safety alert from the FDA warned patients and health care professionals about a possible increased risk for cardiovascular events and death with Stalevo in August 2010. This possible safety issue was observed in a clinical trial called the Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) and in a meta-analysis that combined the cardiovascular-related findings from 15 clinical trials comparing Stalevo to carbidopa/levodopa.

Carbidopa and levodopa have been used extensively and have not been shown to have an increased cardiovascular risk. The FDA was concerned that the entacapone in Stalevo was responsible for these cardiovascular risks because the comparison drugs do not contain this ingredient.

Source: FDA, October 26, 2015; Reuters, October 27, 2015.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function